Hsbc Holdings PLC lifted its position in shares of DaVita Inc. (NYSE:DVA – Free Report) by 71.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 133,080 shares of the company’s stock after acquiring an additional 55,553 shares during the period. Hsbc Holdings PLC’s holdings in DaVita were worth $15,110,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC lifted its position in DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares in the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of DaVita in the 2nd quarter worth $43,000. Caitlin John LLC purchased a new position in shares of DaVita in the fourth quarter worth $34,000. Sankala Group LLC bought a new position in shares of DaVita during the fourth quarter valued at $39,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of DaVita during the third quarter valued at $46,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at DaVita
In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. The trade was a 27.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Read Our Latest Stock Analysis on DaVita
DaVita Stock Performance
DaVita stock opened at $213.31 on Friday. The stock has a market cap of $13.69 billion, a PE ratio of 19.79, a price-to-earnings-growth ratio of 0.70 and a beta of 0.91. DaVita Inc. has a one year low of $101.00 and a one year high of $215.33. The stock has a fifty day moving average of $187.13 and a 200 day moving average of $152.04.
DaVita (NYSE:DVA – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The business’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period last year, the firm posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, sell-side analysts predict that DaVita Inc. will post 15.07 EPS for the current fiscal year.
DaVita Profile
DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
See Also
- Five stocks we like better than DaVita
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
